Comparison of the effects of heparin and the direct factor Xa inhibitor, rivaroxaban, on bone microstructure and metabolism in adult rats

Abstract

Rivaroxaban leads to fewer adverse effects on bone microstructure than heparin.

Effects of unfractionated heparin and rivaroxaban on the expression of heparanase and fibroblast growth factor 2 in human osteoblasts

“…In our previous study, it was found that unfractionated heparin had a more marked adverse effect on bone microstructure and function, compared with rivaroxaban (9). The present study showed that rivaroxaban inhibited the expression of FGF2, whereas unfractionated heparin repressed the expression of HPSE and FGF2.…”

“…The overexpression of HPSE and FGF2 overcame the adverse effects of unfractionated heparin and rivaroxaban. In our previous study, it was found that treatment with unfractionated heparin and rivaroxaban for 4 weeks had negative effects on bone microstructure and function in adult rats (9). Therefore, the results of the present in vitro study suggested that the negative effects of long-term treatment with unfractionated heparin or rivaroxaban on bone health were due to their ability to inhibit the growth of osteoblasts.…”

“…A previous study reported that rivaroxaban did not impair fracture healing in a rat femur fracture model (6). By contrast, other studies have found that long-term treatment with rivaroxaban had negative effects on bone metabolism and microstructure in vitro and in vivo (7)(8)(9), although rivaroxaban had fewer adverse effects on bone health, compared with heparin (9). However, the mechanisms underlying the negative effects of unfractionated heparin and rivaroxaban remain to be fully elucidated.…”

The effect of a new oral anticoagulant (Rivaroxaban) on implants pull-out strength. An experimental study in rats

“…Since Heparin and LWMH effects are dose dependent we used the maximum dose in order to have clear and obvious results. Resent study 28 for the effects of Heparin and Rivaroxaban on bone microstructure and metabolism (bone quality and quantity) found that Rivaroxaban leads to fewer adverse effects on bone.…”

Η Επίδραση Των Από Του Στόματος Χορηγούμενων Αντιπηκτικών Φαρμάκων Στην Οστική Ενσωμάτωση Ορθοπαιδικών Εμφυτευμάτων

“…Συγκεκριμένα υπάρχουν ενδείξεις ότι το Rivaroxaban δεν επηρεάζει την διαδικασία της οστικής επούλωσης [85][86][87] και την επιμετάλλωση των οστικών κυτάρων 86 . Τούτο πιθανότατα οφείλεται στην παροδική δράση του Rivaroxaban στα οστικά κύτταρα και στην προσαρμογή των κυττάρων και την αντισταθμιστική του δράση μέσω άλλων μηχανισμών 85,86,[88][89][90][91] . Στο αντικείμενο όμως που υπάρχει παντελής έλλειψη δημοσιεύσεων και μελετών για όλα τα νεότερα από του στόματος αντιπηκτικά και ειδικότερα για το Rivaroxaban είναι για την επίδρασή του στην οστεοενσωμάτωση των υλικών και προθέσεων που χρησιμοποιούνται στην καθημερινή ορθοπαιδική χειρουργική πράξη ταυτόχρονα με την χορήγηση αντιπηκτικών.…”